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Electrostatically-guided inhibition 
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Polypeptide aggregation into amyloid is linked with several debilitating human diseases. Despite 
the inherent risk of aggregation-induced cytotoxicity, bacteria control the export of amyloid-prone 
subunits and assemble adhesive amyloid fibres during biofilm formation. An Escherichia protein, 
CsgC potently inhibits amyloid formation of curli amyloid proteins. Here we unlock its mechanism of 
action, and show that CsgC strongly inhibits primary nucleation via electrostatically-guided molecular 
encounters, which expands the conformational distribution of disordered curli subunits. This delays 
the formation of higher order intermediates and maintains amyloidogenic subunits in a secretion-
competent form. New structural insight also reveal that CsgC is part of diverse family of bacterial 
amyloid inhibitors. Curli assembly is therefore not only arrested in the periplasm, but the preservation 
of conformational flexibility also enables efficient secretion to the cell surface. Understanding how 
bacteria safely handle amyloidogenic polypeptides contribute towards efforts to control aggregation in 
disease-causing amyloids and amyloid-based biotechnological applications.
The formation of amyloid fibres by proteins is widely-known to endanger organism health1. Yet many organisms 
are able to safely direct particular proteins or peptides into fibrous amyloid structures, and thus benefit from the 
self-assembling, stable structure2. Such ‘functional amyloids’ are found in prokaryotes and eukaryotes where they 
play diverse roles such as protein storage3, extracellular matrices4–6, epigenetic inheritance7, silk formation8, mel-
anin production9, and bacteriocidal immune responses10. By controlling early and intermediate stages of amyloid 
formation, organisms are able to avoid any undesirable side-effects from amyloidogenesis. The study of functional 
amyloid systems will therefore yield insights into treatment of disease-causing amyloidoses and aid in the devel-
opment of bio-materials and anti-biofilm strategies11.
The curli system of gram-negative bacteria is one of the best-understood functional amyloids12,13. Curli fibres 
are surface-attached, extracellular appendages that contribute towards surface adhesion and biofilm formation5. 
The main fibre component, CsgA, is thought to form a compact, parallel β -helix structure that aggregates into 
amyloid fibres, however little is known regarding the intermediate steps en route14. Curli fibres are distinct from 
other bacterial fimbriae in that subunit folding and multimerisation occurs extracellularly15. CsgA subunits are 
efficiently exported by the CsgEG complex where CsgA assembles into fibres that are attached to the cell sur-
face16,17. The bacterium employs two proteins – CsgF and CsgB – to control the location and structural templat-
ing, respectively, of this nucleation event. Thus a picture emerges of a cascade of interactions that efficiently steers 
aggregation-prone CsgA monomers into an amyloid fibre whilst avoiding toxicity.
In order to maximise secretion efficiency, CsgA should be maintained in a relatively high-energy folding state 
until it arrives outside the cell. Recently, we reported that CsgC potently inhibits the formation of amyloid fibres 
by CsgA18. CsgC is not irreversibly incorporated into fibres and is effective at extreme substoichiometric ratios 
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(i.e. even in a 102–103 molar excess of CsgA). Discouraging inappropriate amyloid intermediates from forming 
in the periplasm would not only benefit secretion but also cell vitality as early oligomeric species are often cyto-
toxic19. Thus dealing with oligomers – either by reconfiguring, dissociating, or capping them – could be a way by 
which CsgC efficiently inhibits amyloid formation. In this report we provide new insight into the mechanism of 
CsgC inhibition. We extend this family of amyloid inhibitors and identify CsgH as a new member despite limited 
sequence homology. We also present kinetic, biochemical, and biophysical analyses and unveil the mechanism by 
which CsgC and CsgH affect amyloid formation.
Results
CsgH and CsgC adopt the same structural fold. Until recently the curli operon was only known to be 
present amongst Enterobacteriales, eminently within Escherichia and Salmonella. A search of sequence databases 
revealed that curli-like operons occur throughout several bacterial kingdoms, albeit with a greater degree of 
genetic diversity12. Outside of γ -proteobacteria, the standard twin operons consisting of csgDEFG and csgBAC are 
generally unified into a single, minimal operon that lacks clear homologues of csgC and the master biofilm regula-
tor csgD. An additional gene was also identified within α -proteobacteria, termed csgH, which bears little sequence 
homology to other curli genes12. However, when considering likely secondary structure, putative disulphides, and 
genetic location (adjacent to the subunit genes), CsgH display some resemblance to CsgC (Fig. S1).
To shed more light on this intriguing similarity used sequential iterations of PSI-BLAST to obtain 299 unique 
CsgC/CsgH sequences. These homologues were clustered in two dimensions according to pair-wise sequence 
similarity using CLANS (Fig. 1). We define a protein as a CsgC-like or CsgH-like according to its disulphide bond-
ing pattern (i.e. CsgC homologues have a C × C motif whereas the cysteines are distant in sequence within CsgH 
homologues). CsgH was initially discovered in α -proteobacteria, however there are also distinct sub-families in 
γ -, β -, and δ -proteobacteria as well as Bacteroidetes. The detectable sequence similarity between CsgH and CsgC 
suggests that they may share the same ancestral origins. It is also worth noting that CsgH sequences are far more 
diverse than CsgC, which likely reflects the nature of its substrate, CsgA. CsgA sequences are extremely varied 
in strains carrying CsgH-like genes, with variations in operon organisation and numbers of amyloid repeats and 
even the number of curli subunits, and this is particularly notable for the Bacteriodetes12.
Since CsgC and CsgH display significantly different sequences, we elucidated the structure of CsgH using 
nuclear magnetic resonance (Fig. 2A–C and Table 1). The structure reveals seven β -strands arranged in an identi-
cal configuration to CsgC. One notable difference is the location of the disulphide bond, which staples the N- and 
C-terminal strands together in CsgH (Fig. S1). Structural alignment between CsgH and CsgC (rmsd = 2.6 Å) 
underlines their similarity despite the level of sequence identity being below 20%. In fact, the most similar struc-
ture to CsgH within the current PDB archive is CsgC.
CsgH is a functional homologue of CsgC. Conservation of structure between CsgC and CsgH may indi-
cate that they utilise this particular fold for the same function, or it could reflect the stability of this ancient pro-
tein fold. The fact that no operons exist containing both csgC and csgH is also supportive of functional homology. 
Previous studies have shown that CsgC is a potent inhibitor of CsgA amyloid formation18. We therefore tested 
whether CsgH has analogous inhibitory properties using the Thioflavin T (ThT) fluorescence assay to monitor 
Figure 1. Phylogenetic distribution of CsgC- and CsgH-like sequences. Distinct families of CsgC- and 
CsgH-like sequences occur across gram-negative bacterial phyla. The CsgC group is tightly-defined whereas 
CsgH can be split into several sub-types. The red lines connecting dots represent relatively-close sequence 
homology.
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its effect on CsgA amyloid formation. Indeed, recombinant CsgH from Rhodopseudomonas palustris was able to 
inhibit amyloid formation of E. coli CsgA in a dose-dependent manner at potencies similar to CsgC (Fig. 2D–E).
Given that CsgC and CsgH can inhibit the fibrillation of amyloidogenic proteins outside of their natural curli 
operon we tested their effectiveness against a unrelated bacterial amyloid protein: FapC from Pseudomonas aerug-
inosa4. Using the ThT assay we mixed samples of recombinant FapC with CsgC (or CsgH) at a range of substoi-
chiometric molar ratios. Remarkably both proteins were potent inhibitors of FapC amyloid formation, with CsgH 
being slightly more effective than CsgC (Fig. 2F).
CsgC delays the appearance of fibrillar structures in vitro. To determine at what stage in amyloid 
formation CsgC functions, we explored negative-stain electron microscopy to provide a qualitative visualization 
of CsgA aggregation. Images were recorded at 0, 0.5, 1, 2, 3, 5 and 22 hours post-purification (Fig. 3A; Fig. S2). 
CsgA fibrils are observed already at the 0.5 hour time point in the absence of CsgC. Extended CsgA fibres at later 
time-points exhibit a high degree of plasticity (Fig. 3A). However, constituent double filaments were sufficiently 
thin, linear and homogenous (~10 nm diameter) to be studied by single-particle analysis. Short segments of dou-
ble filaments were extracted, aligned and classified. In contrast to the helical architecture observed for RepA oli-
gomers20 and amyloid β -protein protofibrils21, 2D class averages of CsgA filaments showed stacked parallel lines 
lacking a clear helical structure (Fig. 3C). Filaments are seen exhibiting a twist, however the repeat unit was too 
large and variable for helical parameters to be assigned.
To give a visual appreciation of the effect of CsgC on CsgA fibre formation, an equivalent time course was 
performed in parallel in the presence of the inhibitor at a substoichiometric molar ratio of 1:200 (Figs 3B and S2). 
In contrast to CsgA alone, early time-points showed fewer higher-order assemblies. The presence of small fibre 
networks became prevalent only at around the 2 hour time point and later. These data suggest that CsgC interacts 
either with bulk, monomeric CsgA to inhibit the subsequent formation of higher order species, or with intermedi-
ates on the pathway to the formation of the oligomers. Single-particle analysis of double filaments formed by CsgA 
in the presence of CsgC did not reveal any structural differences compared to those formed by CsgA alone (data 
not shown). In support of this, we obtained both CD and ATR-FTIR spectra of CsgA amyloid fibres formed in the 
presence or absence of CsgC and observed no significant difference between the two sets of spectra (Fig. 3D,E).
Chemical kinetics reveals CsgC inhibits primary nucleation and elongation of CsgA. We further 
explored the mechanism of CsgC inhibition of CsgA amyloid formation by analysing the kinetics of CsgA fibril 
formation in the presence and absence of CsgC. The kinetics of ordered amyloid aggregation reactions can be 
described mathematically by considering distinct steps that lead to formation of mature fibres from monomeric 
subunits; nucleation, elongation and, where relevant, secondary nucleation and fragmentation22. Different inte-
grated rate laws describing the kinetics are obtained, dependent upon the presence or absence of each of these 
Figure 2. CsgH is a structural and functional homologue of CsgC. (A) Ensemble of 20 lowest-energy 
structures calculated for CsgH (PDB 2N59). (B) Cartoon structure of the lowest-energy CsgH structure 
coloured according to the rainbow from N- (blue) to C-terminus (red). (C) Crystal structure of CsgC (PDB 
2Y2Y) shown for comparison. Addition of (D) CsgH or (E) CsgC, respectively, at a range of substoichiometric 
molar ratios leads to a dose-dependent inhibition in the kinetic profile of CsgA amyloid formation within the 
ThT assay. (F) Addition of CsgC (solid lines) or CsgH (dashed lines) at various substoichiometric ratios results 
in a dose-dependent inhibition of FapC amyloid formation.
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steps in the aggregation mechanism, as well as their possible saturation. These can then each be fitted globally 
to multiple ThT fluorescence curves for aggregation reactions, using our data analysis platform, AmyloFit22. The 
quality of these fits are compared, and if only one mechanism gives an accurate fit, then it is likely the correct one. 
The fits to the integrated rate law describing the correct mechanism will yield the monomer dependence and rate 
constants of the individual microscopic processes.
In the case of CsgA in isolation, unseeded aggregation experiments monitored by ThT fluorescence were per-
formed. These data are well-described by a model that includes primary nucleation and elongation, but excludes 
secondary nucleation and fragmentation (see Supplementary Methods and Fig. S10). This provides strong evi-
dence that secondary nucleation and fragmentation do not occur in CsgA aggregation.
Interestingly, we find that data from unseeded CsgA + CsgC experiments can be fitted to the same model, 
which shows that CsgC has a perturbative effect on CsgA aggregation, and does not change the underlying mech-
anism of aggregation. It furthermore suggests that CsgC is not depleted significantly during aggregation, i.e. its 
binding to aggregating CsgA species is reversible. We do, however, obtain different values of the combined k+kn 
nucleation-and-elongation rate constant at each CsgA/ CsgC ratio, which becomes increasingly inhibited as the 
relative concentration of CsgC increases (Fig. 4A).
In order to separate the relative effect of inhibition on nucleation and on elongation, additional experiments 
were performed in which CsgC was added to an aggregating CsgA reaction at various intermediate timepoints 
(Fig. 4B). The mathematical form of the kinetic model was then simplified, using the fact that primary nucleation 
is first-order in CsgA concentration under the experimental conditions used. A further mathematical analysis of 
the simplified model revealed a way to analyse these experiments to calculate accurate separated inhibition fac-
tors for nucleation and for elongation (see Supplementary Methods for full details). These data analyses revealed 
that CsgC induces a reduction in both the primary nucleation rate and the elongation rate (Fig. 4B, inset). At a 
CsgC:CsgA ratio of 1:400 the nucleation rate is reduced by a factor of approximately 2–4 times whereas elongation 
inhibition is approximately 1.2–2 times. This result is consistent with EM observations in which the appearance 
of fibrillar structures is delayed by CsgC. Considering the low molar ratio of CsgC used, we therefore conclude 
that CsgC perturbs CsgA nucleation by inhibiting the formation of some low-concentration intermediate species 
along the aggregation pathway.
NMR and Refinement statistics for CsgH





Sequential (|i-j|) = 1) 200
Medium range (|i-j|) < 4) 54
Long range (|i-j|) > 5) 373
Ambiguous Distance Constraints 519




Violations (mean and SD)
 Distance constraints (Å) 0.25 ± 0.55
 Dihedral angle constraints (°) 0.5 ± 0.6
 Maximum dihedral angle violation (°) 4.93
Energies
Mean Constraint Violation Energy 283 ± 14.1
Mean amber energy − 2680 ± 43.5
Maximum distance constraint violation (Å) 0.49 ± 0.26
Mean deviations from idealized geometry
 Bond length (Å) 0.0062 ± 0.0002
 Bond angle (°) 0.629 ± 0.017
Average Pairwise rmsd (Å) (Residues 1–98)
 Heavy 1.01 ± 0.10
 Backbone 0.42 ± 0.11
Ramachandran plot
% in most favoured regions 94.5% ± 1.3%
% in allowed regions 99.4% ± 0.6%
% in disallowed regions 0%
Table 1.  Structural restraints and refinement statistics for CsgH. The statistics shown are for the final 
ensemble of 20 structures. The error shown represents one standard deviation from the mean.
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Figure 3. Negative stain EM images documenting a time-course for nucleating fibres. Representative images 
from (A) CsgA and (B) CsgA + CsgC fibre formation are shown. CsgC was added at a substoichiometric ratio 
of 1:200. Time points for 0, 0.5, 2, 5 and 22 hours are shown (see additional. Scale bar = 200 nm. Additional 
examples for each time point are shown in Figs S2 and S4. (C) 2D Class average and corresponding raw 
images for CsgA double filament architecture. Scale bar, 16 nm. Panels (D,E) show ATR-FTIR and CD spectra, 
respectively, of CsgA fibres grown for 24 hrs in the absence or presence of CsgC (200:1 molar ratio).
Figure 4. Kinetic analysis of the effect of CsgC on CsgA amyloid formation. (A) Addition of CsgC at a range 
of substoichiometric ratios results in progressive inhibition of CsgA, which was fitted to a nucleation-elongation 
model [cite Nat Prot]. The change in k + kn with inhibitor concentation is shown inset. (B) Addition of CsgC 
1:400 at timepoints indicated by legend (in hours). The series truncated at these timepoints can be treated as 
seeded assays and fitted to a seeded nucleation-elongation model. This allows for the relative contributions 
of inhibition of nucleation and of elongation to the overall inhibition of k + kn to be separated. This clearly 
demonstrates a primary inhibitory effect on nucleation with a smaller effect on elongation.
www.nature.com/scientificreports/
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CsgC affects the conformational distribution CsgA within early, disordered ensembles. In 
combination with previous results18,23, our findings suggest that CsgC interacts transiently with CsgA at an early 
point in its transition to amyloid. We investigated the general structure of CsgA during these early stages, and 
establish what differences are induced by CsgC. Firstly, we compared 1H-NMR spectra of freshly-purified CsgA in 
the absence or presence of CsgC (200:1 molar ratio). As shown previously, CsgC does not induce any substantial 
folding of CsgA, however it seems to on the have a small effect average, disordered ensemble structure as evi-
denced by small peak shifts and sharpening of their linewidths (Fig. S3A).
Next we used ATR-FTIR to discover if CsgC influences the secondary structure profile of CsgA. Using 
freshly-purified samples of 40 uM CsgA and a 1:200 molar ratio of CsgC:CsgA we collected Amide-I band spec-
tra (Fig. S3B). One explanation for the ATR-FTIR data is that CsgC induces minor alterations in the average CsgA 
structure as the broad peak centred at ~1650 cm−1 representing disordered polypeptide is shifted in the CsgA 
+ CsgC sample. Although this scenario consistent with the NMR data and these data were taken at a very early 
time point, there may also be a contribution to these ATR-FTIR spectra from oligomeric species with β structure, 
which would be lower when CsgC is present.
Finally, we explored the overall hydrodynamic state of CsgA at its earliest stages post-purification. Since we 
postulate that CsgC inhibits nucleation by diverting CsgA from aggregation-prone conformations, we might 
expect purified CsgA to be more monodisperse in the presence of CsgC. We used SEC-MALS to test this idea 
(Fig. S3C). During gel filtration, the main CsgA peak displayed an initial shoulder, for which the molecular weight 
calculation reports the presence of low-population species larger than a monomer. Conversely, when inhibited by 
CsgC, CsgA eluted as a more monodisperse, monomeric species. We also used pulsed field gradient (PFG)-NMR 
to measure the diffusion constant of CsgA in the absence and presence of CsgC (at a 200:1 molar ratio). When 
mixed with CsgC, the self-diffusion coefficient (D) of CsgA 1.13 × 10−10 m2/s. In isolation, this value decreased 
slightly to 1.03 × 10−10 m2/s. This trend is consistent with the above findings as, in the presence of CsgC, bulk 
CsgA diffuses faster, i.e. as more freely diffusing species.
Electrostatic effects dominate CsgA-CsgC interactions. 2D 1H-15N NMR spectra of 20 μM CsgC or 
CsgH in the presence of a 3-fold excess of CsgA display a subtle chemical shift and linewidth perturbations for a 
few specific peaks, which likely indicates a weak and low population interaction with CsgA (Fig. S4). Although 
these shifts do not group tightly into a binding surface, they decorate the perimeter of the β 4-β 5 edge of CsgH. As 
the NMR titration required much higher CsgA concentrations and inhibitor ratios than normally used in amyloid 
formation assays, and coupled with the sensitivity of amyloid kinetics to monomer concentrations and liquid 
interfaces, we reverted to site-directed mutagenesis and the ThT fluorescence assay to elucidate the recognition 
determinants between CsgA and CsgC (or CsgH). Guided by the general localisation of NMR perturbation we 
initially targeted highly-conserved, surface-exposed residues, however we also made simultaneous surface muta-
tions within individual β -strands to alter more dramatically the chemical environment. Mutated CsgCs were 
checked by 1D NMR to confirm that the surface mutations did not affect overall folding (Fig. S4B).
The most dramatic loss of potency were observed in CsgC mutants in which a positively charged side-chain 
was switched to a negatively charge one or where negative charge was introduced (see Fig. 5A). We observed a 
loss of potency for two other charge-related CsgC mutants, whereas point mutations that do not involve charge 
had no significant effect on CsgC activity (Fig. S4A,B). We also tested the least potent CsgC mutants against FapC 
amyloid formation in the ThT assay. Once again, interference with charged side-chains had a detrimental effect 
on inhibition (Fig. S5C). Rather surprisingly, mutation of conserved CXC motif (C37S mutant) or kink-inducing 
proline residue (P29) within the 2nd β -strand had little effect on potency in this assay (Fig. S5B).
The mutations that caused the severest loss of potency in CsgC are grouped on the protein surface and deco-
rate the perimeter of the β 4-β 5 edge (Fig. 5C). Two charge mutations that little effect on CsgC inhibition (E30H 
and D93S) are distance from this edge of the β -sandwich. We probed further for functionally-relevant surface 
regions by testing CsgC mutants in which 2–3 adjacent, surface-exposed residues along a β -strand were mutated. 
This shotgun approach revealed that strand 2 and N-terminal half of strand 3 are important to CsgC function 
whereas strands 1, 6 and 7 and the disordered C-terminus are not (Fig. S6). The common feature associated 
with every deleterious mutation is that the side-chains are all charged, thus electrostatic interactions appear to 
be important to the recognition of CsgC by CsgA. The electrostatic surface of CsgC shows that the two β -sheets 
display a patch of opposite polarity, with the larger β -sheet being mainly positively-charged (Fig. 5E). This gen-
eral pattern is also conserved in the electrostatic surface of CsgH (Fig. 5F). Guided by our experience with CsgC 
mutants and our observation of conserved electrostatic potential in CsgH, we constructed a set of mutations in 
CsgH and tested their potency in the ThT assay against CsgA. Once again, by switching charge polarity at single 
or multiple sites we observed dramatic loss in potencies (Fig. 5B).
A general conservation of positive charge on the β -sheet surface is seen in many other CsgC and CsgH homo-
logues (Fig. S7). Interestingly we noticed that the closely-related CsgC homologue from Salmonella typhimurium 
(AgfC, 71% sequence identity) displayed a less well-pronounced positively-charged patch, and that three basic 
residues (each critical for potency within CsgC) were replaced by glutamine within AgfC (R40, K57 and K60). 
AgfC is unusual in that its pI is only 0.5 units above CsgA/AgfA subunits, whereas for both CsgH and CsgC the 
pIs are > 2 units higher. We therefore hypothesised that AgfC would be less potent inhibitor of E. coli CsgA than 
its cognate inhibitor CsgC. We expressed AgfC in recombinant form using the same construct design as for CsgC 
and confirmed it was properly folded by NMR and CD spectroscopy (Fig. S8). Despite its high overall sequence 
similarity, AgfC was significantly worse than CsgC at inhibiting CsgA and FapC amyloid formation, which is in 
full agreement with our predictions based on electrostatic considerations (Fig. S8). To probe the specificity of 
the inhibition further, we have tested whether several unrelated protein could inhibit CsgA amyloid formation. 
Two examples were chosen; E. coli maltose binding protein (MBP) which has a low pI but reported periplasmic 
chaperone activity, and an unrelated highly basic protein DfsB from Paenibacillus dendritiformis24. MBP had 
www.nature.com/scientificreports/
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no inhibitory effect on CsgA aggregation, where DfsB did show a modest inhibitory effect, but nowhere near as 
potent as CsgC/H. Taken together this not only highlights the major influence of positive charge in mechanism of 
inhibiting CsgA amyloid, but also a role for electrostatic complementarity in CsgC specificity (Fig. S9).
The inhibitory effect of CsgC is dependent on ionic strength. We continued to explore the hypothe-
sis that the inhibitory function of CsgC is electrostatically-driven by measuring the potency of CsgC in solutions 
of increasing ionic strength, which would be predicted to have a negative effect. Addition of NaCl to samples 
containing CsgA alone resulted in a mild dose-dependent increase in t½ (the time when fluorescence = 0.5 × Fmax) 
and a significant decrease in Fmax (Figs 6A and S9). The fact that CsgA takes longer to reach the plateau with 
increasing ionic strength suggests that charge-charge interactions play a role in amyloid formation. Remarkably, 
we found that the potency of CsgC was also reduced as the NaCl concentration was increased. At 50 and 100 mM 
NaCl CsgC was slightly less potent, however between 200–500 mM its ability to inhibit CsgA decreased sharply 
until it had little effect (Fig. 6B). The marked electrostatic screening of CsgC inhibitory potency suggest a key role 
for electrostatic interactions, likely in driving encounters between CsgC and CsgA.
Discussion
Almost a decade ago it was reported that Salmonella produces different amyloid fibres when its csgC gene (agfC) 
is deleted25. For many years the role of CsgC with curli biogenesis remained obscure. Its apparent restriction to 
Enterobacteria, its low concentration in the periplasm, and a lack of a striking deletion phenotype caused it to 
receive much less attention than other proteins of the curli system.
While CsgC has been shown to be a potent inhibitor of CsgA amyloid formation, the mechanism by which it 
acts has remained unknown18,23. The discovery of CsgH, a novel curli-associated protein from α -proteobacteria, 
and the subsequent solution structure described here reveal that although the amino acid residue sequences of 
CsgC and CsgH are dissimilar (< 20% identity), their structures are remarkably alike. A wider search for CsgC- 
and CsgH-like proteins revealed at least another distinct clade in Pseudomonas. Despite the large differences 
in sequence to CsgC, R. palustris CsgH is also potent inhibitor of amyloid formation by E. coli CsgA. This is all 
the more remarkable when one considers the fact that a single point mutation in CsgC (e.g. K74E) is able to 
reduce its potency dramatically, and that a much closer functional homologue from Salmonella (AgfC) is similarly 
ineffective.
One of the most striking observations in this work is the central role of charge to the anti-amyloidogenesis 
mechanisms of both CsgC and CsgH. Electrostatic charge has been shown previously to affect the ability of amy-
loid subunits themselves to self-polymerise26, thus modulating electrostatic encounters may provide a general 
Figure 5. Loss of charged residues in CsgC or CsgH reduces inhibitory potency. Panels (A,B) show the 
relative potency of site-directed mutants of CsgC or CsgH, respectively within the ThT assay. (Define Quad and 
triple mutants). The raw fluorescence data were smoothed by a Savitsky-Golay filter for clarity. The molar ratio 
of CsgC/H to CsgA was 1:200. The ‘Triple’ CsgH mutant was T16D/Q18S/V20S. The ‘Quad’ CsgH mutant was 
K32A/D36S/R45S/K47E. The structural context of each mutation is shown for CsgC and CsgH in panels (C,D), 
respectively. Panels (E,F) show the electrostatic surface potential of CsgC and CsgH, respectively. The top sub-
panels in each show a conserved positively-charged surface in both proteins.
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route to control amyloid. It is worth noting the pI of CsgC/H homologues is on average two pH unit higher that 
the major curli subunit. Electrostatic attraction would accelerate the encounter between CsgC/H and its substrate 
CsgA, and potentially allow exposed β -strands (possible the β 4-β 5 edge) to interact transiently with CsgA and 
divert it away from any productive amyloid-generating structures.
The high potency of CsgH against the curli amyloid formation and shared electrostatic properties with CsgC 
suggests a common mode of action. CsgC/H could compete with CsgA monomers for the growing end of amy-
loid fibril as these are present at only at very low concentrations relative to bulk CsgA. However, the lack of high 
affinity interaction between any CsgA species and CsgC/H and no evidence of CsgC depletion during amyloid 
formation suggest that the capping of fibril ends is unlikely, Furthermore, EM observations of CsgA show that 
the formation of extensive fibrillar networks is delayed in the presence of the inhibitor, which points to CsgC 
acting primarily at stage prior to the formation of high order fiber species. If CsgC only inhibited elongation then 
an overall reduction in fibre length should be observed, not solely a delay in their appearance. Consistent with 
this observation, the global fitting of CsgA amyloid formation kinetics established that CsgC also functions at 
an early stage, inhibiting the primary nucleation rate with a subsequent smaller effect on elongation (the ratio is 
approximately 3:2 for the inhibition of nucleation versus elongation). This also rules out a significant depletion 
of CsgC during the course of the aggregation reaction. We therefore propose that a highly transient interaction 
occurs with either with an aggregation competent conformation of CsgA or an oligomeric species that represents 
a key intermediate en route to fibril formation and extension. Our studies also suggest CsgC does not induce any 
significant degree of secondary structure or multimeric state in CsgA, but increases the conformational distribu-
tion of its disordered ensemble.
We speculate that the precursors of the major nucleating species on the pathway to curli amyloid (CsgA*) 
manifest themselves as soluble, dynamically-fluctuating, monomeric species, in which the free energy landscape 
Figure 6. Electrostatic screening effects of NaCl on CsgA amyloid formation and inhibition by CsgC.  
(A) Addition of 0–500 mM NaCl to CsgA samples in the ThT assay causes a minor, dose-dependent reduction in 
the rate of amyloid formation. The intensity of ThT fluorescence also decreased by up to ~60% across the range 
Fig. S12. (B) The inhibitory potency of CsgC is gradually reduced as the NaCl concentration is increased. CsgC 
was added at a substoichiometric molar ratio of 1:200 throughout.
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is shallow with a large number of conformations associated with energy minima and small barriers between 
them (Fig. 7). CsgC-like inhibitors act either by diverting bulk CsgA away from forming CsgA* or by interfer-
ing with another species on the nucleation pathway. The lack of the observation of a high-affinity interaction 
between CsgC and CsgA indicates these are very transient encounters and low-population species. We show that 
electrostatic attraction drives this encounter which in turn stabilises the disordered ensemble likely through a 
conformational expansion. This proposed mechanism for CsgC inhibition is akin to that observed for certain 
types of entropy-driven interactions with disordered proteins. In such examples the presence of the ligand causes 
enhanced flexibility in the polypeptide, which results in an entropic expansion with an increased number of states 
becoming accessible27. Electrostatic charge has been shown previously to affect the potency of amyloid inhibitors, 
or the ability of the subunits themselves to self-polymerise26,28–30. Thus the electrostatic mechanism of amyloid 
inhibition described here may represent a more general route to controlling amyloid formation.
In the biological context of curli biogenesis, the role of CsgC is likely to maintain CsgA in a 
secretion-competent conformation within the periplasm (Fig. 7). Recent structures of the curli secretion chan-
nel CsgG shows that it is only large enough to capture a monomer of CsgA31–33. The conformational restric-
tion imposed by this capture drives secretion of CsgA via an entropy-driven transport mechanism. Clearly, the 
presentation of CsgA to the CsgG-CsgE secretion complex is likely to be important for its subsequent diffusion 
through the pore. The ability of CsgC to inhibit the first stages of amyloid formation – nucleation – and maintain 
a disordered and dynamic ensemble is consistent with its physiological role within the bacteria. Kinetic stabiliza-
tion of the disordered ensemble would enable the CsgG-CsgE complex to efficiently recruit monomeric CsgA and 
perform secretion. Given the potency of CsgC against general amyloid formation it is conceivable that organisms 
may secrete CsgC-like factors to purposely inhibit the formation of amyloid by a competitive species.
Methods
Expression & purification of CsgA. The gene encoding the mature form of CsgA (residues 22–151) was 
amplified by PCR from E. coli BL21 (DE3) genomic DNA and ligated into pET28a using NcoI/XhoI sites. CsgA 
was expressed and purified as described34, with minor modifications as described in Supplementary Material.
CsgH expression and purification. The csgH gene from Rhodopseudomonas palustris strain DX-1 was 
codon-optimised and synthesised by GeneArt (Life Technologies). From sequence/structural comparison with 
CsgC, we expressed a CsgH construct starting at residue 10. The gene was ligated into pET28 in frame with a 
C-terminal His tag. CsgH was expressed in E. coli SHuffle T7 Express cells (NEB) by growth in LB medium at 
37 °C until the OD600 reached 0.8 units. Expression was induced at 30 °C by addition of 0.5 mM IPTG. The cells 
were lysed and clarified by centrifugation at 17,000 rpm for 45 min. Supernatants were purified using Ni-NTA 
Superflow chromatography (Qiagen). The eluate was gel filtered using a Superdex 75 16/60 size exclusion column 
(GE Healthcare) equilibrated in 10 mM MES pH 6.5, 0.1 M NaCl.
CsgC and AgfC expression and purification. CsgC9-110 with a C-terminal hexahistidine tag was 
expressed and purified as described previously23. An equivalent construct encoding mature AgfC was also cre-
ated. The final purification stage of gel filtration was performed in 10 mM Tris-HCl, 100 mM NaCl, pH 8.0.
FapC expression and purification. FapC was produced as described previously4. For a full description of 
the methodology see Supplementary Materials.
Figure 7. General model that describes inhibition of CsgA by CsgC. The top panel indicates the general 
folding pathway for CsgA from disordered states via a key nucleation-competent intermediate (CsgA*) that 
productively multimerises and matures into amyloid fibrils. Although drawn as a monomer, CsgA* may be an 
oligomer. Fibril ends also capture appropriately structured monomers. Our data are consistent with a model 
whereby CsgC interacts with disordered monomers or CsgA* to prevent nucleation, effectively increasing the 
activation energy (Eact) required to form CsgA*. Within the cell (lower panel) this interaction prevents CsgA* 
formation and keeps CsgA in state readily picked up by CsgE for secretion through CsgG.
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Structure determination of CsgH. The solution structure of CsgH was solved by standard NMR meth-
ods and a combination of manual and automatic assignment. For a full description of the methods used see 
Supplementary Materials. The coordinates of CsgH were deposited in the Protein Data Bank as accession number 
2N59.
Mutagenesis. Single- and multiple-residue mutants of CsgC, CsgH and CsgA were created using the Q5 
Site-Directed Mutagenesis kit (NEB). The expression and purification of site-directed mutants followed the same 
procedure as wild-type protein. The folding status of each mutant was verified by 1D proton NMR spectroscopy.
CsgA ThT assay. ThT assays were performed as described previously18, using 5 μM CsgA in a buffer contain-
ing 50 mM KPO4, 5.5 μM ThT, pH 7.4. Inhibitor proteins were added at substoichiometric ratios between 1:100 
and 1:1000 from a 5 μM stock. Protein samples (100 μL) were aliquoted into a 96-well plate (Corning, Cat. No. 
3881) and sealed with aluminium tape (Costar Cat. No. 6570). Fluorescence measurements at 25 °C were per-
formed using SpectraMax M3e or i3× (Molecular Devices) plate readers with excitation at 438 nm, emission at 
495 nm, and a wavelength cut-off at 455 nm. Readings were taken every 15 min and the plate was shaken for 10 sec 
prior to each reading. Replicate data (n ≥ 3) were averaged and normalised to between 0 and 1.
FapC ThT assay. Purified FapC was diluted in to 75 μM using ice-cold FapC Assay Buffer. Thioflavin T was 
added to 40 μM from a 1 mM stock in ethanol. Aliquots of FapC + ThT were transferred to individual microtubes 
and mixed with varying amounts of inhibitor protein (CsgC, CsgH, AgfC or mutants thereof). A 96-well plate 
was loaded with 145 μL of sample per well and sealed with foil-backed tape. Fluorescence measurements were 
obtained every 10 minutes over a 72 hour period under quiescent conditions at 37 °C using a SpectraMax i3× 
machine. Fluorescence excitation and emission were set to 438 and 480 nm, respectively.
Kinetic fitting of ThT data. ThT assay data for the addition of CsgC at a range of substoichiometric ratios 
were fitted simulutaneously to a general kinetic model22,24. Additions of CsgC 1:400 at timepoints were treated as 
seeded assays and fitted to a seeded saturated-elongation model to separate relative contributions of nucleation 
and of elongation to the inhibition.
Negative Stain Electron Microscopy. CsgA at 35 μM was incubated in Eppendorf tubes at 25 °C with or 
without CsgC (200:1 molar ratio). Aliquots were taken at 0, 0.5, 1, 2, 3, 5, and 22 hours. For each time point, 10 μL 
of sample was applied to glow-discharged carbon-coated copper grids and incubated for 2 min before negative 
staining with 2% uranyl acetate. Samples were imaged at 30,000× on either a Tecnai 12 (FEI) or Tecnai G2 Spirit 
(FEI) microscope operated at 120 kV. Images were recorded on a 2k TemCam F216 (TVIPS) and an Eagle 2k CCD 
(FEI) camera (pixel sizes of 4.48 and 7.31 Å/pixel, respectively). For a description of single-particle analyses see 
Supplementary Materials.
Biophysical measurements. For details of 1D proton NMR, PFG-NMR, SEC-MALS and ATR-FTIR meas-
urements please refer to Supplementary Materials.
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